BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 1331404)

  • 1. Chemical modification and irreversible inhibition of striatal A2a adenosine receptors.
    Jacobson KA; Stiles GL; Ji XD
    Mol Pharmacol; 1992 Jul; 42(1):123-33. PubMed ID: 1635550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling of adenosine receptors. I. The ligand binding site on the A1 receptor.
    IJzerman AP; Van Galen PJ; Jacobson KA
    Drug Des Discov; 1992; 9(1):49-67. PubMed ID: 1457698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 8-(3-Isothiocyanatostyryl)caffeine Is a Selective, Irreversible Inhibitor of Striatal A(2)-Adenosine Receptors.
    Ji XD; Gallo-Rodriguez C; Jacobson KA
    Drug Dev Res; 1993 Aug; 29(4):292-298. PubMed ID: 22787287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiological role of inward rectifier K(+) channels in vascular smooth muscle cells.
    Park WS; Han J; Earm YE
    Pflugers Arch; 2008 Oct; 457(1):137-47. PubMed ID: 18437413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional characterization of an endogenous Xenopus oocyte adenosine receptor.
    Kobayashi T; Ikeda K; Kumanishi T
    Br J Pharmacol; 2002 Jan; 135(2):313-22. PubMed ID: 11815366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a revised nomenclature for P1 and P2 receptors.
    Fredholm BB; Abbracchio MP; Burnstock G; Dubyak GR; Harden TK; Jacobson KA; Schwabe U; Williams M
    Trends Pharmacol Sci; 1997 Mar; 18(3):79-82. PubMed ID: 9133776
    [No Abstract]   [Full Text] [Related]  

  • 7. Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors.
    Niiya K; Jacobson KA; Silvia SK; Olsson RA
    Naunyn Schmiedebergs Arch Pharmacol; 1993 May; 347(5):521-6. PubMed ID: 8321327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the new A2 adenosine receptor antagonist 8FB-PTP, an 8 substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models.
    Dionisotti S; Conti A; Sandoli D; Zocchi C; Gatta F; Ongini E
    Br J Pharmacol; 1994 Jun; 112(2):659-65. PubMed ID: 8075885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of platelet aggregation by adenosine receptor agonists.
    Cristalli G; Vittori S; Thompson RD; Padgett WL; Shi D; Daly JW; Olsson RA
    Naunyn Schmiedebergs Arch Pharmacol; 1994 Jun; 349(6):644-50. PubMed ID: 7969516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further characterization of [3H]-CGS 21680 binding sites in the rat striatum and cortex.
    Kirk IP; Richardson PJ
    Br J Pharmacol; 1995 Jan; 114(2):537-43. PubMed ID: 7881753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influences of different adenosine receptor subtypes on catalepsy in mice.
    Zarrindast MR; Modabber M; Sabetkasai M
    Psychopharmacology (Berl); 1993; 113(2):257-61. PubMed ID: 7855191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain.
    Jarvis MF; Schulz R; Hutchison AJ; Do UH; Sills MA; Williams M
    J Pharmacol Exp Ther; 1989 Dec; 251(3):888-93. PubMed ID: 2600819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the binding of a novel nonxanthine adenosine antagonist radioligand, [3H]CGS 15943, to multiple affinity states of the adenosine A1 receptor in the rat cortex.
    Jarvis MF; Williams M; Do UH; Sills MA
    Mol Pharmacol; 1991 Jan; 39(1):49-54. PubMed ID: 1987452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors.
    Cunha RA; Johansson B; Constantino MD; SebastiĆ£o AM; Fredholm BB
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Feb; 353(3):261-71. PubMed ID: 8692280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists.
    Maemoto T; Finlayson K; Olverman HJ; Akahane A; Horton RW; Butcher SP
    Br J Pharmacol; 1997 Nov; 122(6):1202-8. PubMed ID: 9401787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential for new selective adenosine receptor ligands and metabolism inhibitors.
    Bowmer CJ; Yates MS
    Trends Pharmacol Sci; 1989 Sep; 10(9):339-41. PubMed ID: 2690422
    [No Abstract]   [Full Text] [Related]  

  • 17. [3H]2-phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain.
    Cornfield LJ; Hu S; Hurt SD; Sills MA
    J Pharmacol Exp Ther; 1992 Nov; 263(2):552-61. PubMed ID: 1331404
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.